



## Top 10 Sellers Around the World

From Pullan's Pieces #215

Eric Hayes

Eric@pullanconsulting.com

This time I am doing a bit of a world tour of what analysts think will be the top 10 drugs in the year 2031 (as searched in GlobalData).

### Top 10 in the US in 2031 (USD Millions)

Drug Name	Company	TA	Target	Molecule Type	2024	2031(F)
Zepbound	Eli Lilly	Metabolic	GLP1 Receptor	Peptide	4,926	27,858
Mounjaro	Eli Lilly	Metabolic	GLP1 Receptor	Peptide	8,950	22,104
Skyrizi	AbbVie	Immunology	IL 23 Subunit Alpha	MAB	10,086	20,362
Dupixent	Sanofi	Dermatology	IL4R Subunit Alpha	MAB	10,325	19,705
Ozempic	Novo Nordisk	Metabolic	GLP1 Receptor	Peptide	12,213	16,360
Biktarvy	Gilead	Infection	HIV1 Integrase	Small Mol.	10,855	13,310
Wegovy	Novo Nordisk	Metabolic	GLP1 Receptor	Peptide	6,639	11,726
Rinvoq	AbbVie	Immunology	JAK1	Small Molecule	4,259	10,215
Cagrisema	Novo Nordisk	Metabolic	GLP1 Receptor	Peptide	-	9,325

In the US analyst forecasts for 2031, obesity dominates (with immunology, derm and infection for other TAs). Along with the obesity

peptides are 2 small molecules and 2 MABs. The sales are in the tens of billions.

### Top 10 in Europe (USD Millions)

Drug Name	Company	TA	Target	Molecule Type	2024	2031(F)
Cagrisema	Novo Nordisk	Metabolic	GLP1 Receptor	Peptide	-	4,857
Wegovy	Novo Nordisk	Metabolic	GLP1 Receptor	Peptide	1,090	4,755
Dupixent	Sanofi	Dermatology	IL4R Subunit Alpha	Mab	1,750	4,101
Enhertu	Daiichi Sankyo	Oncology	DNA Topo I	ADC	981	3,642
Ozempic	Novo Nordisk	Metabolic	GLP1 Receptor	Peptide	2,321	3,543
Rybelsus	Novo Nordisk	Metabolic	GLP1 Receptor	Peptide	1,035	2,287
Vabysmo	Roche	Ophthalmology	Angiopoietin 2	MAB	706	2,193
Ocrevus	Roche	CNS	B cell CD20	Mab	1,483	1,971
Entyvio	Takeda	Gastrointestinal	Integrin Alpha 4	Mab	1,492	1,898

In Europe, along with the obesity drugs and dupixent in derm, we see the oncology ADC Enhertu, the ang2 ophthalmology drug Vabysmo, a CNS CD20, and a GI integrin in the top 10. Sales are in the single digit billions.

### Top 10 in Japan (USD Millions)

Drug Name	Company	TA	Target	Molecule Type	2024	2031(F)
Epetraborole	AN2 Therapeutics	Infection	Leu tRNA Ligase Cytoplasmic	Small mol.	-	1,706
Leqembi	Eisai	CNS	Amyloid Beta PP	MAb	83	789
Opdivo	Ono	Oncology	PD1	MAb	789	740
Enhertu	Daiichi Sankyo	Oncology	DNA Topo I K Transport	ADC	203	707
Takecab/Vocinti	Takeda	Gastrointestinal	ATPase Alpha Chain 1	Small Mol.	652	692
Tarlige	Daiichi Sankyo	CNS	VDCC Subunit Alpha2/Delta1	Small Mol.	365	512
Tivdak	Genmab	Oncology	Tissue Factor	ADC	-	485
Kostaive	Arcturus Therapeutics	Infection		mRNA Vaccine	-	477
Hemlibra	Roche	Heme Disorders	Coag. Factor IX	MAb	417	465

In Japan, obesity is not visible in the top 10. An anti-infective tops the list, followed by CNS, oncology, GI and including heme disorders. There are companies not in the top 20 for global sales. Most of the top 10 have sales below \$1B.

### Top 10 in China (USD Millions)

Drug Name	Company	TA	Target	Molecule Type	2024	2031(F)
Gardasil/ Gardasil 9	Merck & Co	Oncology	HPV Major Capsid Protein L1	Subunit Vaccine	-	1,657
Wegovy	Novo Nordisk	Metabolic	GLP1 Receptor	Peptide	28	1,539
Mazdutide	Innovent Biologics	Metabolic	GLP1 Receptor	Peptide	-	1,452
Ozempic	Novo Nordisk	Metabolic	GLP1 Receptor	Peptide	836	1,083
Tyvyt	Innovent Biologics	Oncology	PD Protein 1	MAb	-	990
Kangyueda	KeyMed Biosciences	Dermatology	IL4R Subunit Alpha	MAb	-	911
Ketanil	Akeso	Oncology	CTLA4	MAb	-	853
Focus V	Sino Biopharmaceutical	Oncology	VEGFR	Small Mol.	-	711
KarXT	Zai Lab	CNS	Receptor M1	Small Mol.	-	675

For China, obesity is back in the top 10, but Gardasil, an oncology HPV vaccine tops the list. Local company "fast followers" are apparent and most of the top forecasted drugs are not yet launched (presumably a reflection of the rapidly evolving pharmaceutical environment). To get into the top 10, sales are above \$500M.

**The marketplace for drugs is not yet homogeneous around the world.**

---



---